General MedicationsORALGeneric
CRIXIVAN
INDINAVIR SULFATE
Standard Dose
EQ 333MG BASE
Max Dose
Refer to approved labeling
Primary Use
Review priority: 901 REQUIRED Marketing status: Discontinued
Summary
Approval overview CRIXIVAN is listed in Drugs@FDA under application 020685 (NDA).
Review priority: 901 REQUIRED Marketing status: Discontinued Active ingredient INDINAVIR SULFATE Form and strength CAPSULE;ORAL - EQ 333MG BASE Sponsor MERCK SHARP DOHME Submission history Latest submission status date: 2016-09-15 00:00:00.
Structured Monograph
Clinical summary
Approval overview CRIXIVAN is listed in Drugs@FDA under application 020685 (NDA). Review priority: 901 REQUIRED Marketing status: Discontinued Active ingredient INDINAVIR SULFATE Form and strength CAPSULE;ORAL - EQ 333MG BASE Sponsor MERCK SHARP DOHME Submission history Latest submission status date: 2016-09-15 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: 901 REQUIRED
Interaction Notes
- No interaction notes stored yet.